Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
ESDR070 - Treating Bullous Pemphigoid by Inhibiting FcRn: A Phase 2/3 Trial with Efgartigimod
Home
Publications
ESDR070 - Treating Bullous Pemphigoid by Inhibiting FcRn: A Phase 2/3 Trial with Efgartigimod
ESDR070 - Treating Bullous Pemphigoid by Inhibiting FcRn: A Phase 2/3 Trial with Efgartigimod
Authors:
RH
Russell Hall
Russell Hall
DC
Donna Culton
Donna Culton
ZL
Zhi Liu
Zhi Liu
HU
Hideyuki Ujiie
Hideyuki Ujiie
ES
Enno Schmidt
Enno Schmidt
DM
Dedee Murrell
Dedee Murrell
IS
Ivaylo Stoykov
Ivaylo Stoykov
PV
Peter Verheesen
Peter Verheesen
LB
Luca Borradori
Luca Borradori
PJ
Pascal Joly
Pascal Joly
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Publisher website
Google Scholar
23 September 2022
conference paper
Published by
Morressier GmbH
DOI:
10.26226/m.62fa009023ef91001a663bab
Abstract
Efgartigimod (EFG) is an engineered Fc fragment that inhibits the activity of the neonatal Fc receptor (FcRn), thereby reducing the levels of cir | POSTER
Keywords
TREATING BULLOUS
BULLOUS PEMPHIGOID
INHIBITING FCRN
EFGARTIGIMOD EFGARTIGIMOD
EFG
POSTER
EFGARTIGIMOD
FCRN
TREATING
PHASE
Related articles
Scroll to top